Stocks and Investing Stocks and Investing
Wed, August 25, 2021
Tue, August 24, 2021

Marc Frahm Downgraded (TBPH) to Hold and Decreased Target to $14 on, Aug 24th, 2021


Published on 2024-10-27 17:44:44 - WOPRAI, Marc Frahm
  Print publication without navigation


Marc Frahm of Cowen & Co., Downgraded "Theravance Biopharma, Inc." (TBPH) to Hold and Decreased Target from $42 to $14 on, Aug 24th, 2021.

Marc has made no other calls on TBPH in the last 4 months.



There is 1 other peer that has a rating on TBPH. Out of the 1 peers that are also analyzing TBPH, 0 agree with Marc's Rating of Hold.



This is the rating of the analyst that currently disagrees with Marc


  • Vikram Purohit of "Morgan Stanley" Maintained at Buy with Decreased Target to $27 on, Friday, July 16th, 2021
Contributing Sources